NEW YORK (GenomeWeb) — The Mayo Clinic and biomedical investing firm Invenshure have launched a new company, Oneome, to provide analysis of NGS data and reporting of relevant pharmacogenomic information in an accessible format.

Terms of the investment were not disclosed, but John Logan Black, co-founder of the new company and co-director of the Mayo Clinic's Personalize Genomics Lab, told GenomeWeb Daily News that the company is 50 percent owned by Mayo and 50 percent owned by Invenshure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.